Abstract:Primary angle-closure glaucoma (PACG) is one of the leading causes of irreversible blindness in Asian populations. Its pathogenic mechanism involves the interaction of multiple factors, including pupillary block, non-pupillary block (lens factors, plateau iris, ciliary body anterior rotation), and dynamic choroidal expansion. Although traditional filtering surgery can effectively lower eye pressure, complications such as bleb leakage, infections, persistent hypotony, and malignant glaucoma remain prominent, imposing a heavy postoperative management burden. Minimally invasive glaucoma surgery (MIGS), characterized by micro-incisions, minimal conjunctival damage, and rapid postoperative recovery, has developed into major technical systems, including angle-based procedures (GATT, KDB), Schlemm''s canal stents (iStent, Hydrus), ciliary body modulation procedures (ECP, MP-TSCPC, UCP), and subconjunctival drainage procedures (XEN). This article, based on the different pathological mechanisms of PACG, reviews the intervention targets of various MIGS, their clinical efficacy and safety evidence at different disease stages, discusses current challenges and directions for individualized treatment, and provides evidence-based references for the minimally invasive management of PACG.